In a letter to US president Donald Trump, the Association for Accessible Medicines – along with a host of other pharmaceutical and healthcare bodies and associations – has urged the administration to not implement policies that “restrict access to, or destabilize the supply chain for, currently available pharmaceuticals or medical devices.”
Referring to potential changes to the ‘Buy American’ provisions, the AAM said that, while it encourages incentives to increase manufacturing...





